BioNexus Gene Lab没有发行零碎股份，而是根据反向拆股前十个交易日的成交量加权平均价格 (VWAP)向股东提供现金支付。公司已更正此前报告的现金支付价格，确保股东获得适当价值的零碎股份补偿。

The Company’s 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth.

Investing.com — BioNexus Gene Lab Corp (NASDAQ: BGLC )，一家市值447万美元的医疗实验室服务提供商，已宣布将从周一开盘起实施普通股反向拆股。此举旨在解决公司在纳斯达克规则下的最低竞价价格不足问题。根据 InvestingPro 数据，BGLC股价在过去一年下跌超过57%，目前交易价格为0.25美元。

BioNexus Gene Lab Corporation (BGLC) shares tumbled to a 52-week low, touching down at $0.22, with a price-to-book ratio of just... ByInvesting.com • Dec 20, 2024 BGLC stock touches 52-week low ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> ...

About BioNexus Gene Lab Corp. BioNexus Gene Lab Corp. (Nasdaq: BGLC) is a Wyoming-incorporated, Nasdaq-listed company with operating subsidiaries in Malaysia focused on molecular diagnostics and ...

19:50 EDT BioNexus Gene Lab (BGLC) Corp trading halted, news pending Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks. Make smarter ...

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group ...

KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (Nasdaq: BGLC) ("BioNexus” or the "Company”), a diversified biotechnology and specialty materials group headquartered ...